Interestingly, confirming these results, a recent study, with a machine-learning approach, has identified in the CSF quantifiable protein biomarkers discriminating AD from other neurological diseases and demonstrated that SIRT2 shows a very high discriminatory performance with higher CSF levels in AD patients as compared to controls (Gaetani et al. 2021). The gene discussed is SIRT2; the disease is nervous system disorder.